Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18125594 | 0.81 | CYP3A4 (0.33) | CYP3A4TSHRCYP2C19 | |
| SCHEMBL19117686 | 0.75 | CYP2A6 (0.41) | MAPTPIK3CBSCN9A | |
| SCHEMBL23346951 | 0.73 | PIK3CB (0.42) | ABL1SRCMAPTPIK3CB | |
| SCHEMBL3570930 | 0.73 | RXFP1 (0.35) | MAPTCYP3A4PIK3CBSCN9A | |
| SCHEMBL18534997 | 0.73 | PIK3CB (0.34) | MAPTPIK3CBSCN9A | |
| SCHEMBL29777078 | 0.73 | PIK3CB (0.34) | MAPTCYP2C19PIK3CBSCN9A | |
| SCHEMBL29942174 | 0.73 | RXFP1 (0.35) | MAPTCYP3A4PIK3CBSCN9A | |
| SCHEMBL20987529 | 0.73 | PIK3CB (0.38) | ABL1SRCMAPTPIK3CBSCN9A | |
| SCHEMBL22863238 | 0.73 | PIK3CB (0.34) | MAPTCYP2C19PIK3CBSCN9A | |
| SCHEMBL21894120 | 0.73 | CDC7 (0.32) | CYP3A4TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | ABL1 3943/4885SRC 3746/4885MAPT 2516/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ABL1 3943/4885SRC 3746/4885MAPT 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.